Patients with high-risk endometrial cancer, who are under the care of gynecologic oncologists, have improved survival rates, according to a study published online Jan. 24 in the Journal of Clinical Oncology.
FRIDAY, Jan. 28 (HealthDay News) -- Patients with high-risk endometrial cancer, who are under the care of gynecologic oncologists, have improved survival rates, according to a study published online Jan. 24 in the Journal of Clinical Oncology.
John K. Chan, M.D., from the University of California School of Medicine in San Francisco, and colleagues analyzed data on 18,338 women, obtained from Medicare and Surveillance, Epidemiology, and End Results databases from 1988 to 2005. Their goal was to determine how influential gynecologic oncologists were in the treatment and survival of patients with endometrial cancer.
The researchers found that 21.4 percent of the women received care from gynecologic oncologists (group A); whereas, 78.6 percent were treated by other physicians (group B). Group A patients were older, had more lymph nodes removed, presented with more advanced-stage cancers (stages III to IV), had higher-grade tumors, and were more likely to be treated with chemotherapy. The five-year disease-specific survival (DSS) of group A was higher than group B in women with stages II to IV disease (79 versus 73 percent) and in women with advanced-stage (III to IV) disease (72 versus 64 percent). However, treatment by a gynecologic oncologist was not associated with a DSS advantage among patients with stage I cancers.
"Directed care by gynecologic oncologists was associated with more extensive lymph node resection and subsequent adjuvant therapy. Most importantly, care provided by gynecologic oncologists improved the survival of those with high-risk (stages II to IV, grade 2 and 3, and high-risk histologies) disease," the authors write.
AbstractFull Text (subscription or payment may be required)
Related Content
Balancing VTE and bleeding risks in gynecologic cancer surgeries
December 6th 2024A comprehensive analysis shows the benefits of thromboprophylaxis often outweigh the bleeding risks during gynecologic cancer procedures, though patient-specific risk factors are crucial for decision-making.
Read More
Shift towards neoadjuvant chemotherapy found in ovarian cancer treatment
October 21st 2024A recent study shows a significant decrease in primary cytoreductive surgery utilization for advanced ovarian cancer, as neoadjuvant chemotherapy followed by interval cytoreductive surgery gains acceptance for its noninferior survival outcomes and reduced postoperative morbidity.
Read More
Family history criteria used to predict breast cancer genetic risk variants
September 26th 2024In a recent study, patients with a positive response to the Seven-Question Family History Questionnaire were more likely to present with a pathogenic or likely pathogenic variant in the BRCA1 and BRCA2 genes.
Read More